Cargando…

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

BACKGROUND: Low absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC may also be associated with response to immunotherapy. This study explores whether response to PD1 inhibitors in recurrent and/or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Won Jin, Yarchoan, Mark, Hopkins, Alex, Mehra, Ranee, Grossman, Stuart, Kang, Hyunseok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117944/ https://www.ncbi.nlm.nih.gov/pubmed/30170629 http://dx.doi.org/10.1186/s40425-018-0395-x

Ejemplares similares

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
por: Diehl, Adam, et al.
Publicado: (2017)

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)
por: Jung, Kyungsuk, et al.
Publicado: (2018)

Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma
por: Chen, Miao-Fen, et al.
Publicado: (2018)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma
por: Shimanuki, Marie, et al.
Publicado: (2018)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Prognostic significance of combined pretreatment lymphocyte counts and body mass index in patients with head and neck cancer treated with radiation therapy
por: Wu, Yao‐Yu, et al.
Publicado: (2018)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Mean level of pretreatment neutrophil to lymphocyte ratio in patients with squamous cell carcinoma of the head and neck–Cross-sectional study
por: Khan, Saqib Raza, et al.
Publicado: (2023)

Squamous cell carcinoma of head and neck: what internists should know
por: Jung, Kyungsuk, et al.
Publicado: (2020)

Phospho-(T356)RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
por: Beck, Tim N., et al.
Publicado: (2015)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

Pretreatment neutrophil to lymphocyte ratio in determining the prognosis of head and neck cancer: a meta-analysis
por: Yu, Yalian, et al.
Publicado: (2018)

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
por: Mehra, Ranee, et al.
Publicado: (2018)

Prognosis Value of Platelet Counts, Albumin and Neutrophil-Lymphocyte Ratio of Locoregional Recurrence in Patients with Operable Head and Neck Squamous Cell Carcinoma
por: Ye, Jing, et al.
Publicado: (2020)

Pretreatment oral hygiene habits and survival of head and neck squamous cell carcinoma (HNSCC) patients
por: Friemel, Juliane, et al.
Publicado: (2016)

Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma
por: Fu, Ze-Ming, et al.
Publicado: (2022)

PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma
por: Simon, C, et al.
Publicado: (1999)

High pretreatment neutrophil‐to‐lymphocyte ratio as a predictor of poor survival prognosis in head and neck squamous cell carcinoma: Systematic review and meta‐analysis
por: Yang, Lin, et al.
Publicado: (2018)

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
por: Foy, Jean-Philippe, et al.
Publicado: (2022)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis
por: Levy, Dylan A., et al.
Publicado: (2022)

Biomarkers predictive of response to pembrolizumab in head and neck cancer
por: Pfister, David G., et al.
Publicado: (2022)

Pretreatment dietary intake is associated with tumor suppressor DNA methylation in head and neck squamous cell carcinomas
por: Colacino, Justin A., et al.
Publicado: (2012)

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
por: Siano, Marco, et al.
Publicado: (2017)

Tumour-infiltrating lymphocytes in the risk stratification of squamous cell carcinoma of the head and neck
por: Jones, T M
Publicado: (2014)

Age-related changes in T lymphocytes of patients with head and neck squamous cell carcinoma
por: Jeske, S. S., et al.
Publicado: (2020)

Characteristics of B lymphocyte infiltration in HPV(+) head and neck squamous cell carcinoma
por: Zhang, Siwei, et al.
Publicado: (2021)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
por: Chow, Laura Q.M., et al.
Publicado: (2016)

Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma()()
por: Xu, Qiaoshi, et al.
Publicado: (2016)

Bioinformatics analysis for the biomarkers of the tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma
por: You, Yuanhe, et al.
Publicado: (2021)

Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study
por: Cho, Jae-Keun, et al.
Publicado: (2018)

PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
por: Müller, Tim, et al.
Publicado: (2017)

Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck
por: Zahnreich, Sebastian, et al.
Publicado: (2021)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
por: Baba, Yuh, et al.
Publicado: (2012)

Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer
por: Price, James M., et al.
Publicado: (2022)

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2016)

PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma
por: Shen, Bin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vihoofnumnsjoul4lkbin8q6qu